Research programme: B-Raf kinase inhibitors - Eli Lilly and Company
Latest Information Update: 28 Apr 2024
At a glance
- Originator Deciphera Pharmaceuticals
- Developer Deciphera Pharmaceuticals; Eli Lilly and Company
- Class Small molecules
- Mechanism of Action Proto oncogene protein b raf inhibitors; Raf kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malignant melanoma; Solid tumours
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 04 May 2022 Deciphera Pharmaceuticals intends to nominate candidate from pan-RAF inhibitor research program in 2022
- 14 Apr 2022 Preclinical development is ongoing for Solid tumours in USA (Deciphera Pharmaceuticals pipeline, April 2022)